Katherine Brenda Xiong
Clinical Assistant Professor, Pediatric Neurology
Clinical Focus
- Epilepsy
Academic Appointments
-
Clinical Assistant Professor, Pediatric Neurology
Professional Education
-
Board Certification: American Board of Psychiatry and Neurology, Epilepsy (2024)
-
Fellowship: Stanford University Pediatric Epilepsy Fellowship (2024) CA
-
Board Certification: American Board of Psychiatry and Neurology, Neurology with Special Qualifications in Child Neurology (2023)
-
Residency: Stanford University Child Neurology Residency (2023) CA
-
Residency: Stanford University Dept of Pediatrics (2020) CA
-
Medical Education: UT Southwestern (2018) TX
All Publications
-
Clinical validation of autoSCORE: A human-in-the-loop AI tool for interpretation of long-term EEG recordings.
Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
2026; 193: 2112430
Abstract
To validate autoSCORE, a convolutional neural network (SCORE-AI) implemented into a commercially available EEG reader, for analysis of long-term EEG (LT-EEG) recordings, and to evaluate it within the human-in-the-loop approach.autoSCORE automatically divides LT-EEG into 2-hour segments, labeling each as normal or as containing one or more of four abnormality categories: focal epileptiform, generalized epileptiform, focal non-epileptiform, or diffuse non-epileptiform. In abnormal segments, it also inserts markers defined by start/stop times and tagged by abnormality type. Within each category, markers can be ranked by decreasing probability. Eighty 2-hour LT-EEG segments (40 in-hospital, 40 ambulatory) from patients aged 0.9-82.3 years were analyzed by autoSCORE. The diagnostic reference standard was derived from independent conventional visual assessment by three human experts.Accuracy computed across expert-expert and AI-expert pairings, evaluated at the level of the 2-hour segments, were comparable, except for detection of focal non-epilepiform abnormality, where AI outperformed experts for identification accuracy (p = 0.019). The positive predictive value of the automated abnormality markers was 0.446-0.823. In the human-in-the-loop workflow, inspecting 10 automated markers with the highest probability in each category enabled correct identification of all abnormal segments, corresponding to 1.5%-5.5% of the full 2-hour segment.autoSCORE accurately screens LT-EEG recordings and may serve as an adjunct to human EEG interpretation to reduce the workload of human experts.autoSCORE is a validated tool that can increase the productivity and efficacy of human experts in assessment of LT-EEG to improve patient diagnosis and management strategies.
View details for DOI 10.1016/j.clinph.2026.2112430
View details for PubMedID 42868974
-
A prospective natural history study protocol for clinical trial readiness in synaptic disorders.
Epilepsia
2026
Abstract
STXBP1-related disorder (STXBP1-RD) and SYNGAP1-related disorder (SYNGAP1-RD) are two common genetic synaptopathies that are associated with epilepsy, developmental delay, intellectual developmental disorder, and behavioral problems. Both STXBP1-RD and SYNGAP1-RD are potential targets for disease-modifying therapies, but there is limited information in the literature describing the natural history of either disorder, which impedes outcome selection for future clinical trials. The objective of this study is to develop a framework to better define and outline the clinical spectrum and longitudinal trajectories of STXBP1-RD and SYNGAP1-RD natural history, including development, behavior, seizure histories, and electrophysiology.Here, we describe a protocol, regulatory structure, and supportive preliminary data for multicenter, prospective natural history studies of STXBP1-RD (STARR) and SYNGAP1-RD (ProMMiS). The protocols incorporate gold standard clinician-administered outcome measures including the Bayley Scales of Infant and Toddler Development 4th edition, Gross Motor Function Measure-66, fine motor domains of the Peabody Developmental Motor Scales 3rd edition, parent-reported outcome measures, epilepsy histories, and biomarker exploration. To date, the study has enrolled 164 individuals with STXBP1-RD and 159 with SYNGAP1-RD, with ongoing longitudinal assessments every 6 months in a subset of approximately 200 total individuals across both disorders.Our data support that existing developmental measures are feasible, informative, and show minimal floor or ceiling effects. Furthermore, we demonstrate that medical record-based seizure history reconstruction reveals unique epilepsy trajectories while minimizing burden to families. We observe disease-specific patterns of developmental performance and distinct longitudinal seizure dynamics, highlighting the need for data generation in a gene/disorder-specific manner for clinical trial readiness.In summary, we present a feasible natural history protocol with prospective data for two complex neurodevelopmental disorders with natural histories that have previously been incompletely characterized, within a regulatory framework that will support the use of these data to expedite clinical trial development.
View details for DOI 10.1002/epi.70374
View details for PubMedID 42446932
-
Targeted Treatments for Genetic Epilepsies, Part 1: Channelopathies
CURRENT TREATMENT OPTIONS IN NEUROLOGY
2026; 28 (1)
View details for DOI 10.1007/s11940-026-00873-x
View details for Web of Science ID 001794356400001
-
Current and Emerging Precision Therapies for Developmental and Epileptic Encephalopathies.
Pediatric neurology
2025; 168: 67-81
Abstract
Developmental and epileptic encephalopathies (DEEs) are severe neurological disorders characterized by childhood-onset seizures and significant developmental impairments. Seizures are often refractory to treatment with traditional antiseizure medications, which fail to address the underlying genetic and molecular mechanisms. This comprehensive review explores the evolving landscape of precision therapeutics for DEEs, focusing on mechanism-driven interventions across key pathophysiologic categories. Targeted approaches for channelopathies include antisense oligonucleotides and gene therapies, such as zorevunersen and ETX101 for SCN1A-related Dravet syndrome, alongside novel small molecules for other ion channel disorders. Advances in targeting neurotransmitter receptor dysfunctions, including gamma-aminobutyric acid and glutamate receptor variants, highlight the use of modulators such as gaboxadol, radiprodil, and l-serine, alongside emerging gene therapies. For synaptic dysfunctions, innovative treatments such as chemical chaperones for STXBP1-related disorders and Ras-Raf-MEK-ERK inhibitors for SYNGAP1 pathologies are discussed. The review also examines precision interventions targeting cellular signaling pathways in tuberous sclerosis complex, epigenetic regulation in Rett syndrome, and metabolic interventions like ketogenic diets and targeted supplementation for specific genetic etiologies. Additionally, the importance of enhancing access to genetic testing, conducting robust natural history studies, and employing innovative clinical trial designs is emphasized. Future directions focus on addressing the challenges in developing and implementing gene-based therapies, integrating systems biology, leveraging artificial intelligence for data analysis, and fostering collaboration among stakeholders. The rapidly advancing field of precision therapeutics for DEEs holds promise to improve outcomes through tailored, equitable, and patient-centered care.
View details for DOI 10.1016/j.pediatrneurol.2025.04.010
View details for PubMedID 40381457
-
Education Research: Sustained Implementation of Quality Improvement Practices Is Observed in Early Career Physicians Following a Neurology Resident QI Curriculum.
Neurology. Education
2024; 3 (2): e200137
Abstract
Background and Objectives: The Accreditation Council for Graduate Medical Education and American Board of Psychiatry and Neurology expect engagement in quality improvement (QI) activities for all residents and practicing neurologists. Our neurology residency program instituted an experiential Neurology Residency QI Curriculum in 2015 for all residents. In this study, we aimed to characterize the role of QI engagement in the early-career paths of program graduates.Methods: We distributed an online survey evaluating QI training, scholarship, and leadership (before, during, and after residency training) to all individuals who graduated from our residency program (graduation years 2017-2021). Primary outcomes were QI project leadership or mentorship and QI scholarship (projects, posters, and publications) after residency. Predictors of these outcomes were also evaluated using Fisher exact test.Results: Twenty-nine of 50 graduates (58%) completed the survey. Median time from residency graduation was 3 years. Of the respondents, 14% actively participated in a QI project before residency, 83% during residency, and 48% after graduating. In addition, 41% had led or mentored a QI project and 34% had performed QI scholarship since residency. Fourteen percent of participants held formal roles in QI or patient safety, while 24% received formal full-time equivalents for QI work. Significant predictors (p < 0.05) of QI leadership included older age, time since graduation, rank, and participation in Clinical Effectiveness Leadership Training (CELT-an institutional QI faculty development course). Significant predictors (p < 0.05) of QI scholarship included older age, time since graduation, participation in CELT, and participation in QI scholarship during residency. QI training, participation, and/or project leadership before residency did not predict either QI leadership or scholarship after residency.Discussion: Many neurology residency graduates continued to lead QI projects and produce QI scholarship in the early years after graduation. However, receiving protected time for leadership and academic work in this area is uncommon. Our findings suggest that more infrastructure, including training, career development, and mentorship, can foster neurologists interested in leading in quality and patient safety. In academic models, promotion pathways that support academic advancement for faculty leading in QI are needed.
View details for DOI 10.1212/NE9.0000000000200137
View details for PubMedID 39359889
-
Asymmetric Crying Facies in Newborns and Infants
JOURNAL OF PEDIATRICS
2022; 246: 234
View details for Web of Science ID 000814869400040
-
50 Years Ago in TheJournalofPediatrics: Asymmetric Crying Facies in Newborns and Infants.
The Journal of pediatrics
2022; 246: 234
View details for DOI 10.1016/j.jpeds.2022.04.042
View details for PubMedID 35750392
-
Accelerated identification of disease-causing variants with ultra-rapid nanopore genome sequencing.
Nature biotechnology
2022
Abstract
Whole-genome sequencing (WGS) can identify variants that cause genetic disease, but the time required for sequencing and analysis has been a barrier to its use in acutely ill patients. In the present study, we develop an approach for ultra-rapid nanopore WGS that combines an optimized sample preparation protocol, distributing sequencing over 48 flow cells, near real-time base calling and alignment, accelerated variant calling and fast variant filtration for efficient manual review. Application to two example clinical cases identified a candidate variant in <8 h from sample preparation to variant identification. We show that this framework provides accurate variant calls and efficient prioritization, and accelerates diagnostic clinical genome sequencing twofold compared with previous approaches.
View details for DOI 10.1038/s41587-022-01221-5
View details for PubMedID 35347328
-
Ultra-Rapid Nanopore Whole Genome Genetic Diagnosis of Dilated Cardiomyopathy in an Adolescent With Cardiogenic Shock.
Circulation. Genomic and precision medicine
2022: CIRCGEN121003591
View details for DOI 10.1161/CIRCGEN.121.003591
View details for PubMedID 35133172
-
Ultrarapid Nanopore Genome Sequencing in a Critical Care Setting.
The New England journal of medicine
2022
View details for DOI 10.1056/NEJMc2112090
View details for PubMedID 35020984
-
HRI-mediated translational repression reduces proteotoxicity and sensitivity to bortezomib in human pancreatic cancer cells
ONCOGENE
2018; 37 (32): 4413-4427
Abstract
Human cancer cells display extensive heterogeneity in their sensitivities to the proteasome inhibitor bortezomib (Velcade). The molecular mechanisms underlying this heterogeneity remain unclear, and strategies to overcome resistance are limited. Here, we discover that inherent differences in eIF2α phosphorylation among a panel of ten human pancreatic cancer cell lines significantly impacts bortezomib sensitivity, and implicate the HRI (heme-regulated inhibitor) eIF2α kinase as a novel therapeutic target. Within our panel, we identified a subset of cell lines with defective induction of eIF2α phosphorylation, conferring a high degree of sensitivity to bortezomib. These bortezomib-sensitive cells exhibited impaired translation attenuation followed by toxic accumulation of protein aggregates and reactive oxygen species (ROS), whereas the bortezomib-resistant cell lines displayed increased phosphorylation of eIF2α, decreased translation, few protein aggregates, and minimal ROS production. Importantly, we identified HRI as the primary bortezomib-activated eIF2α kinase, and demonstrated that HRI knockdown promoted cell death in the bortezomib-resistant cells. Overall, our data implicate inducible HRI-mediated phosphorylation of eIF2α as a central cytoprotective mechanism following exposure to bortezomib and provide proof-of-concept for the development of HRI inhibitors to overcome proteasome inhibitor resistance.
View details for DOI 10.1038/s41388-018-0227-y
View details for Web of Science ID 000441144300006
View details for PubMedID 29720726
View details for PubMedCentralID PMC6138554
https://orcid.org/0000-0002-1603-2037